



23 October 2014
EMA/129697/2014
Press Office

Guidelines and concept papers

Adopted during the CHMP meeting 20-23 October 2014

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under [Regulatory/Human/Scientific guidelines](#). Documents for public consultation will also be available under [Document search/Public consultations](#).

Quality Working Party

Reference number	Document	Status
EMA/588901/2014	Reflection paper on Mock Design Space verification protocol	Adopted
EMA/CHMP/QWP/608924/2014	Guideline on Quality of transdermal patches	Adopted for 6-months public consultation

Biosimilar Medicinal Product Working Party

Reference number	Document	Status
CHMP/437/04 Rev 1	Guideline on Similar Biological Medicinal Products	Adopted

Vaccines Working Party

Reference number	Document	Status
EMA/56793/2014	Guideline on Influenza Vaccines	Adopted for 3-months public consultation



Drafting Groups

Reference number	Document	Status
EMA/CHMP/508188/2013	Questions and answers document on benzyl alcohol in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use'	Adopted
EMA/CHMP/508189/2013	Questions and answers document on benzoic acid and benzoates in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use'	Adopted

Central Nervous System Working Party

Reference number	Document	Status
EMA/CHMP/53931/2014	Discussion Paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias	Adopted

Oncology Working Party

Reference number	Document	Status
EMA/629967/2014	Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies	Adopted for 3-months public consultation